According to reports from Business Standard, Brooks Laboratories reported a consolidated net loss of ₹1.79 crore in the quarter ended June 2026, marking a significant reversal from the net profit of ₹9.58 crore recorded during the same quarter in the previous financial year. This represents a complete turnaround in the company's profitability position year-over-year. The company's market capitalization stands at ₹186 crore, representing a decline of 56.5% over the past year, indicating significant investor concerns about the company's financial trajectory. The latest financial data shows the company's TTM revenue stands at ₹83.2 crore, showing a poor sales growth of 2.11% over the past five years.
As reported by Business Standard, the company's sales declined 10.00% to ₹22.96 crore in the quarter ended June 2026, compared to ₹25.51 crore during the corresponding quarter of the previous financial year. According to the latest financial data, the company's TTM revenue stands at ₹83.2 crore, showing a poor sales growth of 2.11% over the past five years. This revenue contraction contributed to the overall deterioration in the company's financial performance during the quarter.
According to the financial data reported by Business Standard, the company's operating profit margin (OPM) declined to -5.88% in the June 2026 quarter, compared to 12.27% in the same quarter of the previous year. The company's operating profit turned negative at ₹1.37 crore versus a positive ₹9.98 crore in the corresponding quarter of the previous year. Additionally, PBDT (Profit Before Depreciation and Tax) turned negative at ₹1.37 crore versus a positive ₹9.98 crore in the corresponding quarter of the previous year, indicating operational challenges during the quarter. The latest financial data shows the company's operating profit margin improved to 3.1% in March 2026, though it remains below the previous year's levels.
As reported by Business Standard, the company's profit before tax (PBT) also turned negative at ₹1.79 crore in the June 2026 quarter, compared to a positive ₹9.58 crore in the corresponding quarter of the previous year. The net loss of ₹1.79 crore reflects the cumulative impact of these operational challenges and revenue decline on the company's overall financial performance during the quarter. The company's EPS stands at -7.40 for the current quarter, indicating significant losses per share. The latest financial data shows the company's PAT improved to ₹141.86 lakh in March 2026 on a standalone basis, though consolidated results remain challenging.
According to the latest market data, Brooks Laboratories faces significant challenges with controlling liabilities of ₹75.7 crore and a low return on equity of -1.91% over the last 3 years. The company's promoter holding has decreased by 13.8% over the last 3 years, indicating reduced confidence from key stakeholders. Despite delivering good profit growth of 26.8% CAGR over the last 5 years, the company's sales growth has been poor at 2.11% over the same period. The company has scheduled its 24th AGM on September 3, 2026 via VC/OAVM, indicating ongoing corporate governance activities amid challenging financial conditions.
